We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (5713)12/11/2019 1:46:26 PM
From: richardred  Read Replies (1) | Respond to of 6789
Added to VCEL today.

To: richardred who wrote (5713)1/6/2020 10:51:51 AM
From: richardred  Respond to of 6789

RE-VCEL Speculation ANIK a past SITT pick acquires a company in sports medicine . IMO this can only help with the speculative appeal of VCEL.

Anika Therapeutics to Acquire Parcus Medical and Arthrosurface

Accelerates Revenue Growth through Broadened Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities, and Expands Pipeline

Conference Call & Webcast January 8 at 8:30 a.m. ET

BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 6, 2020-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has signed agreements to acquire Parcus Medical, a leading, privately-held sports medicine company, and Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients.

Global Cartilage Repair Market to Reach $4.42 Billion by 2023: Industry Driver & Constraint Analysis -